Navigation Links
NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
Date:5/6/2008

SOPHIA ANTIPOLIS, France, May 6 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension. The higher doses of PF-03187207 demonstrated a clinically significant reduction in diurnal intraocular pressure (IOP) from baseline and the highest dose showed consistently more IOP lowering than Xalatan(R) 0.005%, at all study visits and at all individual time points, suggesting a beneficial effect of nitric oxide donation. PF-03187207 is a nitric oxide-donating prostaglandin analog, which is covered by the companies' August 2004 agreement.

On the primary endpoint at 28 days, PF-03187207 showed a 12% improvement over Xalatan(R) 0.005% which did not reach statistical significance. However, a statistically significant advantage over Xalatan(R) 0.005% was observed on a number of secondary endpoints (p<0.05).

Pfizer has taken the decision not to launch a global phase 3 development program for PF-03187207. Nevertheless, Pfizer has reaffirmed its commitment to the ongoing joint research program with NicOx, which aims to identify the most active nitric oxide-donating prostaglandin analogs for development on a global basis.

David Eveleth, Vice-President, Ophthalmology Development at Pfizer, commented: "We believe this phase 2 study for PF-03187207 has provided interesting data. While the study did not meet its primary clinical endpoint and our criteria for launching a global phase 3 program for this compound, we remain committed to our joint research program with NicOx, where the follow-up compounds to PF-03187207 have produced encouraging results."

The research to identify improved nitric oxide-donating prostaglandin analogs is one of the programs covered by the companies' March 2006 agr
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... Benton Communications announces a highly effectiv...tailers struggling to make an economic recovery. ...9 -- Flu fears is the type of challenge that could...according to Dr. David Benton, business growth exp...th system – The Rfactor Intensive . &ldqu...
(Date:11/25/2009)... Nov. 25 When most peop...st. But a chiropractor can also give patients the...bular Joint, which is where your jaw (mandible) co...,, The most common symptoms associated with TMJ...pping of the jaw. But many other symptoms can be ...
(Date:11/25/2009)... Calif., Nov. 25 Onyx ...nced that the company will host two investor event...ember 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET ,,...ations surrounding carfilzomib in relapsed and/or ...st American Society of Hematology (ASH) Annual Mee...
(Date:11/25/2009)... 25 /PRNewswire/ - Sentinelle Medical Inc., a lead...visualization software launches a suite of new lea...edical imaging software platform at this year,s Ra...meeting in Chicago, Nov. 30 - Dec. 5, 2009 (Booth ...e high quality images generated by Sentinelle,s sp...
(Date:11/25/2009)... SPRING, Md., Nov. 25 A... FDA,s Center for Drug Evaluation and Research, ti...Safety, and the FDA," appears in the Nov. 26, 2009..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...scusses FDA efforts to strike a balance between ac...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 4
...o researchers, smokers who eat lots of fruit and v...disease. Over 90 per cent of those with chronic ob...ex-smokers. But only one in five smokers// actuall...ersity of Southampton, UK, have carried out the fi...
...o researchers, those who consume wine in moderatio...s or those who consume other types of alcohol. It ...tion seems to confer some health benefit,// chiefl...least some of the beneficial effects. An ong...
... fact that doctors know the power of a common hear... and heart failure, many patients do not take the ...r medication after a heart attack// can reduce the... take the drugs. A new study finds there is a gap ...
...er is the most widely spread cancer all over the w...are expected to die from breast cancer this year. ...ced breastfeeding may be an important factor fueli...g and childbearing patterns. Together, the studies...
...used antidepressant may help women who suffer from...citalopram, marketed as Celexa, may help women who....// Doctors from the University of Pennsylva...ed 14 days prior to the start of menstruation. Pre...
...o a new research, a daily dose of a soybean nutrie...the "bad", or LDL, cholesterol levels in young men...nefit beyond just supplying essential nutrients. /...ytosterol to help lower cholesterol. Phytosterol i...
Other Medicine News:Health News: Breastfeeding may decrease Breast Cancer Risk 2
(Date:11/25/2009)...v. 25 Praxis Electronic Medical Re...n Academy of Family Physicians, (AAFP) Family Prac...urvey for improving medical quality, health mainte...w ARRA Stimulus legislation. Praxis also ranked #1... effect in determining their salary. Finally, Prax...
(Date:11/25/2009)...5 ERT (Nasdaq: ERES ), ...Company,s President and CEO, and Keith Schneck, th...scheduled to present at the 21st Annual Piper Jaff...ber 1, 2009 in New York City, New York. ,, Inte...ting the Company,s corporate website at http://ww...
(Date:11/25/2009)... 25 Remedium Technologi... foam that stops severe bleeding, won first prize ...tegory of the Global Security Challenge 2009, comp...more than 100 entries from around the world, Remed...rity Summit conference held at the London School o...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Investigational Cancer Drug BSI 201 Showed Clinical Benefit in 62 25 of Patients with Triple Negative Metastatic Breast Cancer and Significantly Prolo 4530 1Investigational Cancer Drug BSI 201 Showed Clinical Benefit in 62 25 of Patients with Triple Negative Metastatic Breast Cancer and Significantly Prolo 4530 2Investigational Cancer Drug BSI 201 Showed Clinical Benefit in 62 25 of Patients with Triple Negative Metastatic Breast Cancer and Significantly Prolo 4530 3Investigational Cancer Drug BSI 201 Showed Clinical Benefit in 62 25 of Patients with Triple Negative Metastatic Breast Cancer and Significantly Prolo 4530 4Investigational Cancer Drug BSI 201 Showed Clinical Benefit in 62 25 of Patients with Triple Negative Metastatic Breast Cancer and Significantly Prolo 4530 5Stepping up minority recruiting 47791 1Stepping up minority recruiting 47791 2Stepping up minority recruiting 47791 3Recent smoking cessation research highlights importance of keeping teens from smoking 47789 1Recent smoking cessation research highlights importance of keeping teens from smoking 47789 2
... Suffer from Lower Body Injuries , , CINCINNATI, ...children are significantly more likely to have low.... The Cincinnati Children,s Hospital Medical Cente...rent body parts are injured in obese children comp...tegies can be developed, was presented May 2 at th...
...tics, LLC announces the release of its newest repo...ell Products. Despite a sluggish economy and cut... stem cell research products is expected to increa...88.9 M in 2009 and just under one billion at the e...ts are in need of a fast, accurate assessment of n...
Other Medicine Technology:The Injured Obese Child: Let's Give Him Some Ankle Support 2The Injured Obese Child: Let's Give Him Some Ankle Support 3BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available 2BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available 3
... long-term transtelephonic monitoring. Simple to ...gin in order to record all pre and post ECG segmen...atient sends the recorded ECG over the telephone t...immediate diagnosis. Use of Heart 2005A is recomme...
HeartView12-Lead ECG Recorder/Transmitter
... information system designed specifically to enabl... streamline their diagnostic, management, and busi...lution. Thousands of laboratory professionals from... unique "case-centric model to be effective and ea...
ABX Micros 60
Medicine Products: